Pancreatic Cancer Research

ResearcherRoyal Surrey County HospitalActive in the last 2 years

Adam Enver Frampton

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1392-2755; OpenAlex author ID A5078407406, A5079994857, A5135921173. Sources: ClinicalTrials.gov.

Their work

Papers
68 (first author 5, last author 13)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
170
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 7 papers · 2014: 6 papers · 2015: 4 papers · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 5 papers · 2020: 4 papers · 2021: 2 papers · 2022: 2 papers · 2023: 9 papers · 2024: 10 papers · 2025: 5 papers · 2026: 3 papers, 1 trial

Papers 50 of 68

  1. Colonization of bile with gammaproteobacteria is associated with reduced survival after surgery for pancreatic cancer in patients receiving gemcitabine-based a… Co-author DOI 10.1016/j.ejso.2026.111396↗
  2. Fluid shear stress enhances pancreatic cancer motility through YAP activation. Co-author DOI 10.1186/s13148-026-02163-4↗
  3. Coordinated immune architecture underlies durable survival in pancreatic cancer Last author DOI 10.64898/2026.04.29.721612↗
  4. Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
  5. Impact of social deprivation upon the preoperative pathway and early surgical outcomes after pancreatoduodenectomy for PDAC and non-PDAC periampullary cancer i… Co-author DOI 10.1016/j.hpb.2025.07.007↗
  6. Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms. Co-author DOI 10.1038/s41467-024-55424-2↗
  7. Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control … Co-author DOI 10.1136/bmjopen-2024-094505↗
  8. Venous Resection During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma-A Multicentre Propensity Score Matching Analysis of the Recurrence After Whi… Co-author DOI 10.3390/cancers17071223↗
  9. Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hpb.2024.04.009↗
  10. Five-year recurrence/survival after pancreatoduodenectomy for pancreatic adenocarcinoma: does pre-existing diabetes matter? Results from the Recurrence After W… Co-author DOI 10.1016/j.hpb.2024.04.010↗
  11. Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cells. Co-author DOI 10.1016/j.ijrobp.2023.10.035↗
  12. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  13. What are the true benefits of robotic pancreaticoduodenectomy for patients with pancreatic cancer? Last author DOI 10.1080/17474124.2024.2351398↗
  14. Is oncolytic adenoviral-mediated immunotherapy through p53-overexpression the solution to refractory pancreatic ductal adenocarcinoma? Last author DOI 10.1080/17474124.2024.2363222↗
  15. Metabolites derived from gut microbiota mitigate chemoresistance in pancreatic cancer. Co-author DOI 10.1080/17474124.2024.2412045↗
  16. Implications of the microbiome after pancreatic cancer resection with regard to morbidity and mortality. Last author DOI 10.1080/17474124.2024.2427648↗
  17. The microbial composition of pancreatic ductal adenocarcinoma: a systematic review of 16S rRNA gene sequencing. Last author DOI 10.1097/js9.0000000000001762↗
  18. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13046-024-03090-z↗
  19. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers. Co-author DOI 10.1001/jamanetworkopen.2023.31197↗
  20. Pseudotime dynamics of T cells in pancreatic ductal adenocarcinoma inform distinct functional states within the regulatory and cytotoxic T cells. Co-author DOI 10.1016/j.isci.2023.106324↗
  21. Graphene Sensor Arrays for Rapid and Accurate Detection of Pancreatic Cancer Exosomes in Patients' Blood Plasma Samples. Co-author DOI 10.1021/acsnano.3c01812↗
  22. Does an extensive diagnostic workup for upfront resectable pancreatic cancer result in a delay which affects survival? Results from an international multicentr… Co-author DOI 10.14701/ahbps.23-042↗
  23. Elevated Glycated Haemoglobin (HbA1c) Is Associated with an Increased Risk of Pancreatic Ductal Adenocarcinoma: A UK Biobank Cohort Study. Co-author DOI 10.3390/cancers15164078↗
  24. Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers15174265↗
  25. Pancreatic Exocrine Insufficiency and the Gut Microbiome in Pancreatic Cancer: A Target for Future Diagnostic Tests and Therapies? Co-author DOI 10.3390/cancers15215140↗
  26. Bile Microbiome Signatures Associated with Pancreatic Ductal Adenocarcinoma Compared to Benign Disease: A UK Pilot Study. Last author DOI 10.3390/ijms242316888↗
  27. Healthcare in England was affected by the COVID-19 pandemic across the pancreatic cancer pathway: A cohort study using OpenSAFELY-TPP. Co-author DOI 10.7554/elife.85332↗
  28. A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers14041020↗
  29. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Co-author PMID 36628279↗
  30. Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. Co-author DOI 10.1016/j.hpb.2021.03.003↗
  31. Which patients benefit from preoperative biliary drainage in resectable pancreatic cancer? Last author DOI 10.1080/17474124.2021.1915127↗
  32. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003084↗
  33. Diagnosing pancreatic ductal adenocarcinoma using plasma extracellular vesicle RNA profiles. Co-author DOI 10.1136/gutjnl-2019-319896↗
  34. "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Up… Co-author DOI 10.3390/cancers12113206↗
  35. The Role of Circular RNAs in Pancreatic Ductal Adenocarcinoma and Biliary-Tract Cancers. Last author DOI 10.3390/cancers12113250↗
  36. Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ajpath.2018.03.020↗
  37. Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-019-11752-2↗
  38. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma? Last author DOI 10.1080/14737159.2019.1622414↗
  39. Pharmacogenetics of treatments for pancreatic cancer. Co-author DOI 10.1080/17425255.2019.1620731↗
  40. Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? Co-author DOI 10.18632/oncotarget.26511↗
  41. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-018-03962-x↗
  42. Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Co-author DOI 10.18632/oncotarget.24873↗
  43. Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2017.04.006↗
  44. The density of mast cells c-Kit+ and tryptase+ correlates with each other and with angiogenesis in pancreatic cancer patients. Co-author DOI 10.18632/oncotarget.19716↗
  45. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.10.013↗
  46. Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. Co-author DOI 10.1080/14737159.2016.1175940↗
  47. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1016/j.ejca.2015.04.006↗
  48. Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis. First author DOI 10.1038/ajg.2015.77↗
  49. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step to… Co-author DOI 10.1186/s13148-015-0162-5↗
  50. Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. Co-author DOI 10.1586/14737159.2015.1112273↗

Trials 1

  1. Exercise to Improve Outcomes in Pancreatic Cancer Principal investigator NCT07710495↗

Closest collaborators

The 25 strongest of 170 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Giovannetti · 32 shared papers, 2013–2026 · strength 3.86
  2. Nabeel Merali · 11 shared papers, 2022–2026 · strength 2.12
  3. Nicola E. Annels · 8 shared papers, 2022–2026 · strength 1.55
  4. Jonathan Krell · 22 shared papers, 2011–2024 · strength 1.49
  5. Keith John Roberts · 9 shared papers, 2021–2026 · strength 1.47
  6. Shivan Sivakumar · 8 shared papers, 2023–2026 · strength 1.41
  7. Long R. Jiao · 21 shared papers, 2011–2024 · strength 1.38
  8. Tarak Agrebi Moumni Chouari · 7 shared papers, 2022–2026 · strength 1.29
  9. Daniel Liu · 7 shared papers, 2019–2024 · strength 0.85
  10. Geert Kazemier M · 8 shared papers, 2013–2024 · strength 0.83
  11. Dongmei Deng · 3 shared papers, 2024–2026 · strength 0.78
  12. Leandro Castellano · 14 shared papers, 2011–2019 · strength 0.72
  13. Justin Stebbing · 14 shared papers, 2011–2019 · strength 0.68
  14. Tessa Y. S. Le Large · 7 shared papers, 2014–2024 · strength 0.67
  15. Duncan R.C. Spalding · 6 shared papers, 2012–2025 · strength 0.66
  16. Zaed Z. R. Hamady · 4 shared papers, 2023–2025 · strength 0.66
  17. Ingrid Garajová · 6 shared papers, 2014–2024 · strength 0.64
  18. Tamara Gall · 11 shared papers, 2013–2019 · strength 0.62
  19. Laura L. Meijer · 6 shared papers, 2015–2024 · strength 0.62
  20. Juan Deng · 2 shared papers, 2024–2026 · strength 0.61
  21. Niccola Funel · 8 shared papers, 2013–2022 · strength 0.55
  22. Rachael J. M. Bashford-Rogers · 3 shared papers, 2023–2026 · strength 0.54
  23. Michael Loran Dustin · 3 shared papers, 2023–2026 · strength 0.54
  24. Annalisa Comandatore · 3 shared papers, 2023–2024 · strength 0.48
  25. Jisce R. Puik · 3 shared papers, 2023–2024 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.